CZEN 001

Drug Profile

CZEN 001

Alternative Names: CZEN-001

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zengen
  • Class Melanocyte-stimulating hormones; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Alopecia areata; Pressure ulcer; Seborrhoeic dermatitis; Vitiligo
  • No development reported Pruritus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pruritus in USA (Topical, Gel)
  • 14 Jul 2005 Clinical trials in Alopecia-areata in USA (unspecified route)
  • 14 Jul 2005 Clinical trials in Decubitus ulcer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top